A carregar...
C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
BACKGROUND AND AIM: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7755182/ https://ncbi.nlm.nih.gov/pubmed/33351844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0244370 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|